본문 바로가기
KERD
논문KCI 등재

Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for Non-small Cell Lung Cancer

최병옥|한대희|강진형|장홍석|이상남|김영균|김연실|박재길|안명임|유이령|윤세철|왕영필|이동수
대한암학회 (Korean Cancer Association)|2011.03|Cancer Research and Treatment|제43권 제1호|pp. 32-41

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Prognostic factorNon-small cell lung cancerConcurrent chemoradiationRecurrent non-small cell lung cancer
주제분류의학일반

초록

Purpose To evaluate treatment outcomes and prognostic factors in non-small cell lung cancer (NSCLC)patients treated with concurrent chemoradiation. Materials and Methods From January 2005 to June 2009, 51 patients were treated with concurrent chemoradiation for 3 different aims: locally advanced stage III, locally recurrent disease, and postoperative gross residual NSCLC. Median age was 63 years. Distribution of stages by the 6th edition of American Joint Committee on Cancer (AJCC) was as follows: IIIA (37.3%), IIIB (56.9%). Chemotherapy was administered every week concurrently with radiation using one of the following regimens: paclitaxel (60 mg/m2), docetaxel+cisplatin (20 mg/m2+20 mg/m2), cisplatin (30 mg/m2). Total radiation dose was 16-66.4 Gy (median, 59.4 Gy). Results Median follow-up duration was 40.8 months. The overall response rate was 84.3% with 23complete responses. The median survival duration for the overall patient group was 17.6months. The 3-year survival rate was 17.8%. A total of 21 patients had recurrent disease at the following sites: loco-regional sites (23.6%), distant organs (27.5%). In the multivariate analysis of the overall patient group, a clinical tumor response (p=0.002) was the only significant prognostic factor for overall survival (OS). In the multivariate analysis of the definitive chemoradiation arm, the use of consolidation chemotherapy (p=0.022), biologically equivalent dose (BED)10 (p=0.007),and a clinical tumor response (p=0.030) were the significant prognostic factors for OS.The median survival duration of the locally recurrent group and the postoperative gross residual group were 26.4 and 23.9 months, respectively. Conclusion Our study demonstrated that clinical tumor response was significantly associated with OS in the overall patient group. Further investigations regarding the optimal radiation dose in the definitive chemoradiation and the optimal treatment scheme in locally recurrent NSCLC would be required.

Abstract

Purpose To evaluate treatment outcomes and prognostic factors in non-small cell lung cancer (NSCLC)patients treated with concurrent chemoradiation. Materials and Methods From January 2005 to June 2009, 51 patients were treated with concurrent chemoradiation for 3 different aims: locally advanced stage III, locally recurrent disease, and postoperative gross residual NSCLC. Median age was 63 years. Distribution of stages by the 6th edition of American Joint Committee on Cancer (AJCC) was as follows: IIIA (37.3%), IIIB (56.9%). Chemotherapy was administered every week concurrently with radiation using one of the following regimens: paclitaxel (60 mg/m2), docetaxel+cisplatin (20 mg/m2+20 mg/m2), cisplatin (30 mg/m2). Total radiation dose was 16-66.4 Gy (median, 59.4 Gy). Results Median follow-up duration was 40.8 months. The overall response rate was 84.3% with 23complete responses. The median survival duration for the overall patient group was 17.6months. The 3-year survival rate was 17.8%. A total of 21 patients had recurrent disease at the following sites: loco-regional sites (23.6%), distant organs (27.5%). In the multivariate analysis of the overall patient group, a clinical tumor response (p=0.002) was the only significant prognostic factor for overall survival (OS). In the multivariate analysis of the definitive chemoradiation arm, the use of consolidation chemotherapy (p=0.022), biologically equivalent dose (BED)10 (p=0.007),and a clinical tumor response (p=0.030) were the significant prognostic factors for OS.The median survival duration of the locally recurrent group and the postoperative gross residual group were 26.4 and 23.9 months, respectively. Conclusion Our study demonstrated that clinical tumor response was significantly associated with OS in the overall patient group. Further investigations regarding the optimal radiation dose in the definitive chemoradiation and the optimal treatment scheme in locally recurrent NSCLC would be required.

참고문헌 (24)

  1. Annual report of causes of deaths, 2009, "Korea Central Cancer Registry", Ministry of Health and Welfare, ~ (2009)
  2. Jemal A, "Cancer statistics, 2008", CA Cancer J Clin, 58, pp.71~96 (2008)
  3. Dillman RO, "A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer", N Engl J Med, 323, pp.940~945 (1990)
  4. Le Chevalier T, "Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients", J Natl Cancer Inst, 83, pp.417~423 (1991)
  5. Dillman RO, "Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial", J Natl Cancer Inst, 88, pp.1210~1215 (1996)
  6. Rusch VW, "Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160)", J Clin Oncol, 25, pp.313~318 (2007)
  7. Albain KS, "Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB nonsmall- cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019", J Clin Oncol, 20, pp.3454~3460 (2002)
  8. Zatloukal P, "Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study", Lung Cancer, 46, pp.87~98 (2004)
  9. Socinski MA, "Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial", J Clin Oncol, 22, pp.4341~4350 (2004)
  10. Gandara DR, "Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-smallcell lung cancer: phase II Southwest Oncology Group Study S9504", J Clin Oncol, 21, pp.2004~2010 (2003)
  11. Hanna N, "Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology", J Clin Oncol, 26, pp.5755~5760 (2008)
  12. Albain KS, "Radiotherapy plus chemotherapy with or without surgical resection for stage III nonsmall- cell lung cancer: a phase III randomised controlled trial", Lancet, 374, pp.379~386 (2009)
  13. Leung J, "Survival following radiotherapy for postsurgical locoregional recurrence of non-small cell lung cancer", Lung Cancer, 13, pp.121~127 (1995)
  14. Kelsey CR, "Local recurrence following initial resection of NSCLC: salvage is possible with radiation therapy", Cancer J, 12, pp.283~288 (2006)
  15. Foo K, "Outcome following radiotherapy for loco-regionally recurrent non-small cell lung cancer", Australas Radiol, 49, pp.108~112 (2005)
  16. Furuse K, "Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer", J Clin Oncol, 17, pp.2692~2699 (1999)
  17. Fournel P, "Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint- Etienne d’Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study", J Clin Oncol, 23, pp.5910~5917 (2005)
  18. Sung-Ja Ahn, "Results of Curative Radiation Therapy with or without Chemotherapy for Stage III Unresectable Non-Small Cell Lung Cancer", Cancer Research and Treatment, 37(5), pp.268~272 (2005), 대한암학회
  19. Mudad R, "Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: a dose finding study", Lung Cancer, 39, pp.173~177 (2003)
  20. Firat S, "Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group", Int J Radiat Oncol Biol Phys, 54, pp.357~364 (2002)
  21. Ademuyiwa FO, "Prognostic factors in stage III non-small-cell lung cancer", Clin Lung Cancer, 8, pp.478~482 (2007)
  22. Kelly K, "Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023", J Clin Oncol, 26, pp.2450~2456 (2008)
  23. Park K, "A multinational phase III randomized trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small cell lung cancer (CCheIN): interim analysis", J Clin Oncol, 27(15s), pp.7538~ (2009)
  24. Rengan R, "Improved local control with higher doses of radiation in large-volume stage III nonsmall-cell lung cancer", Int J Radiat Oncol Biol Phys, 60, pp.741~747 (2004)

관련 논문AI추천

Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer김보경, 노재명, 박근칠, 박효정, 선종무, 안명주, 안용찬, 안진석, 오동렬, 이언주, 이혜빈, 표홍렬대한암학회 · Cancer Research and Treatment2015 · 제47권 제4호Results of Curative Radiation Therapy with or without Chemotherapy for Stage III Unresectable Non-Small Cell Lung Cancer김규식, 김영철, 나병식, 남택근, 송주영, 안성자, 윤미선, 정웅기, Kyung-Ok Park대한암학회 · Cancer Research and Treatment2005 · 제37권 제5호Effect of Radiation Therapy Techniques on Outcome in N3-positive IIIB Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy김보경, 김진만, 김진성, 노재명, 박효정, 신정숙, 안용찬, 오동률, 이언주, 주상규, 표홍렬, 홍채선대한암학회 · Cancer Research and Treatment2016 · 제48권 제1호Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer김태규, 남희림, 노재명, 박근칠, 박승규, 선종무, 안명주, 안용찬, 안진석, 이경화, 이언주, 이혜빈, 표홍렬대한암학회 · Cancer Research and Treatment2019 · 제51권 제2호Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status윤탁, 김흥태, 남병호, 문성호, 안혜진, 이건국, 이영주, 임건영, 임근영, 한지연대한암학회 · Cancer Research and Treatment2017 · 제49권 제4호High Dose Involved Field Radiation Therapy as Salvage for Loco-Regional Recurrence of Non-Small Cell Lung Cancer김진국, 남희림, 박근칠, 박희철, 배선현, 심영목, 안명주, 안용찬, 안진석, 표홍렬, Kwhanmien Kim연세대학교의과대학 · Yonsei Medical Journal2012 · 제53권 제6호

이 간행물의 다른 논문 (9건)

Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2008박소희, 이주영, 박은철, 이진수, 공현주, 정규원, 원영주pp. 1-11Prediction of Cancer Incidence and Mortality in Korea, 2011정규원, 이진수, 박소희, 이주영, 원영주, 박은철, 공현주pp. 12-18Phase II Clinical Trial of Genexol􄠶 (Paclitaxel) and Carboplatin for Patients with Advanced Non-small Cell Lung Cancer원종호, 이상철, 박성규, 배상병, 김한조, 김경하, 홍대식, 박희숙, 윤진아, 김찬규, 이남수, 이규택, 김세형, 김현정, 김도진pp. 19-23Effect of Oral Supplementation with Branched-chain Amino Acid (BCAA) during Radiotherapy in Patients with Hepatocellular Carcinoma: A Double-Blind Randomized Study이유미, 성진실, 배정임, 유세환, 이익재, 이종호pp. 24-31Reproductive and Hormonal Factors Associated with Fatty or Dense Breast Patterns among Korean Women이후연, 최귀선, 고경란, 박은철, 전제훈, 강정현, 전재관, 김연주, 오동관, 이창윤pp. 42-48
원문 보기